AIxCrypto Holdings (AIXC) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
18 Aug, 2026Company overview and business model
Operates at the intersection of artificial intelligence and blockchain, focusing on programmable infrastructure for real-world asset (RWA) tokenization and embodied AI systems.
Strategic realignment in 2026 narrowed focus to RWA tokenization and EAI infrastructure, discontinuing early-stage products not aligned with institutional infrastructure goals.
Revenue model includes platform licensing, structuring/transaction fees, and ecosystem participation from the AIxC Hub.
Early-stage commercial collaborations with robotics and autonomous vehicle partners, but no definitive agreements yet.
Financial performance and metrics
No material revenue generated to date from EAI and RWA platforms; operations are in early commercialization stages.
Closed a $41 million PIPE financing in September 2025, supporting the strategic shift and rebranding.
As of August 12, 2026, 20,234,993 shares of common stock outstanding; up to 4,044,975 shares may be issued under the current offering.
Use of proceeds and capital allocation
Proceeds from the equity facility will be used for general corporate purposes, including working capital and investments.
Management retains broad discretion over use of funds; proceeds may be invested in interest-bearing, investment-grade instruments pending deployment.
Latest events from AIxCrypto Holdings
- IPO registers up to 4M shares to fund RoboShare, an early-stage robot-sharing marketplace.AIXC
Registration filing - RoboShare launch prioritized as Q2 expenses drop 32%, but net loss and liquidity risks remain.AIXC
Q2 2026 - Net loss narrowed, but severe liquidity and going concern risks persist despite new capital raised.AIXC
Q4 2024 - Raising up to $4M for cancer drug development, with high dilution and Nasdaq delisting risk.AIXC
Registration filing - Clinical-stage cancer drug developer seeks up to $4M via equity offering amid financial risks.AIXC
Registration filing - Cancer therapeutics firm seeks up to $1.8M via share/warrant offering amid high financial risk.AIXC
Registration filing - Liquidity crisis persists as cash runs low, with urgent need for financing to avoid delisting.AIXC
Q1 2024 - Cancer drug developer seeks up to $3.7M via share/warrant offering amid Nasdaq delisting risk.AIXC
Registration filing - 2025 net loss widened to $16.97M amid strategic realignment and ongoing liquidity risks.AIXC
Q4 2025